Home / Members/ Profile
Ryan  Zarychanski
Hematologist & Senior Scientist
Cancer Care Manitoba and the University of Manitoba
Research Focus:
Hematology and Critical Care

Ryan Zarychanski

Dr. Zarychanski is a Hematologist, Critical Care physician, and Clinician-Scientist at the University of Manitoba and CancerCare Manitoba. His research focuses on the hematologic aspects of critical illness where he leads several national and international randomized trials in the fields of sepsis, anticoagulation and transfusion medicine. He recently served as the Chair for recent adaptive platform trials evaluating anticoagulation strategies in COVID-19 and sepsis, and has contributed to the establishment of a novel trial methods of global collaboration in clinical trials, including the development of the multiplatform randomized trial (mpRCT). 

In collaboration with international partners and building on knowledge generated in COVID-19, Dr. Zarychanski, and co-PIs are preparing to launch a large multi-national adaptive RCT evaluating therapeutic-dose heparin in non-Covid community acquired pneumonia. In Canada, he co-chairs a large multicenter RCT studying plasma exchange in septic shock and leads a cluster-crossover trial to evaluate tranexamic to reduce transfusion in major non-cardiac surgery.

External Links:




Recent work

Writing Committee for the ATTACC/ACTIV-4a/REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD…Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. PMID: 34351721

Writing Committee for the REMAP-CAP/ACTIV-4aAATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, Lawler PR…Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4. PMID: 34351722

Bégin P, Callum J, Jamula E…Zarychanski R, Finzi A; CONCOR-1 Study Group, Arnold DM. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine. 2021 Nov;27(11):2012-2024. doi: 10.1038/s41591-021-01488-2. Epub 2021 Sep 9. PMID: 34504336

Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, Stanworth SJ…Zarychanski R…Gordon AC. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA/Journal of the American Medical Association. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910. PMID: 35315874

Lawler PR, Hochman JS, Zarychanski R. What are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine? Circulation. 2022 Mar;145(9):629-632. doi: 10.1161/CIRCULATIONAHA.121.058113. Epub 2022 Feb 28. PMID: 35226556

REMAP-CAP Investigators, Gordon AC, Mouncey PR, Al-Beidh F…Zarychanski R…Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine/NEJM. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. PMID: 33631065

Boulware DR, Pullen MF, Bangdiwala AS…Zarychanski R…Hullsiek KH. A Randomized Clinical Trial of Hydroxychloroquine as Post-exposure Prophylaxis for Covid-19. NEJM/New England Journal of Medicine. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3. PMID: 32492293.

Zarychanski R, Houston DS. Assessing Thrombocytopenia in the Intensive Care Unit: The Past, Present, and Future. Hematology Am Soc Hematol Educ Program. 2017. Dec 8;2017(1):660-666. doi: 10.1182/asheducation-2017.1.660. PMID: 29222318